Table 1.
Primer | Sequence | Location | Genes | Purpose | Reference |
---|---|---|---|---|---|
seq1 | 5′-CCCCAAAACAGTCTACACAG-3′ | 5′UTR | CYP21A2 and CYP21A21P | Sequencing | Present study |
seq2 | 5′-GGCCCGAATTTCTGAGTCA-3′ | Exon1 | CYP21A2 and CYP21A21P | Sequencing | Present study |
seq3 | 5′-TGTGGTGGTGCTGAACTC-3′ | Exon2 | CYP21A2 and CYP21A21P | Sequencing | Present study |
seq4 | 5′-AGCAGGGAGTAGTCTCCC-3′ | Exon3 | CYP21A2 (G110)∗ | Sequencing | Present study |
seq5 | 5′-GCTTTCCAGAGCAGAGACC-3′ | Exon3 | CYP21A1P (G110fx21)∗ | Sequencing | Present study |
seq6 | 5′-TTCTGTGAGGTAAGGCTGG-3′ | Exon3/Intron3 | CYP21A2 and CYP21A21P | Sequencing | Present study |
seq7 | 5′-TACTGTGAGAGGCGAGGCTGA-3′ | Intron3 | CYP21A2 and CYP21A21P | Sequencing | Present study |
seq8 | 5′-TTTCTCAGGGTGAGGACCTG-3′ | Exon5/Intron5 | CYP21A2 and CYP21A21P | Sequencing | Present study |
seq9 | 5′-CCTCACTCAGCTCTGAGCACT-3′ | Intron7 | CYP21A2 and CYP21A21P | Sequencing | Present study |
seq10 | 5′-TTGTGCCCTTAGCCTTGC-3′ | Exon8 | CYP21A2 and CYP21A21P | Sequencing | Present study |
seq11 | 5′-TTTCCTCACTCATCCCCAAC-3′ | Intron8 | CYP21A2 and CYP21A21P | Sequencing | Present study |
seq12 | 5′-AAGAACTCCAGAGCTCTGGC-3′ | Exon10 | CYP21A2 and CYP21A21P | Sequencing | Present study |
seq13 | 5′-TCTCAGCTTCATTTCCGTGA-3′ | 3′UTR | CYP21A2 and CYP21A21P | Sequencing | Present study |
CYP779f | 5′-AGGTGGGCTGTTTTCCTTTCA-3′ | 5′ end | CYP21A2 and CYP21A21P | PCR (sense) | 18 |
Tena32F | 5′-CTGTGCCTGGCTATAGCAAGC-3′ | Intron32 | TNXB | PCR (antisense) | 18 |
21BF1 | 5′-CCCAGGTGGGGGCGGACACTA-3′ | 5′ end | CYP21A2 | PCR (sense) | 32 |
XA† | 5′-ACTCCAGGTGGGAGTCAAGAA-3′ | 120-bp del | TNXA | PCR (antisense) | Present study |
Primer seq4 and seq5 are specific to wild-type and mutant of p.G110, respectively.
XA is reverse complementary to the XA-specific antisense primer32.